Prerpints.org logo
Preprint
Review

Healthy Effects of Pomegranate (Punica granatum L.) in Internal Medicine and Dentistry

Altmetrics

Downloads

263

Views

66

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

25 January 2024

Posted:

29 January 2024

You are already at the latest version

Alerts
Abstract
Punica granatum L., commonly known as pomegranate, is a typical fruit of Asia, Mediterranean countries, Middle East and USA areas. While in the ancient time pomegranate was considered an ornamental plant, nowadays numerous scientific studies have highlighted its antioxidant and anti-radical activities, up to consider pomegranate as a “superfood”. Pomegranate presents a high content of natural bioactive compounds (NBCs) and its consumption appears to exert numerous healthy beneficial effects, in particular, in several pathological conditions, namely in patients affected by metabolic syndrome, cancer, nephrolithiasis, urinary tract infections and neurodegenerative diseases. Moreover, recent studies pointed out the possible beneficial action of pomegranate on oral health. For these reasons, the utility of pomegranate in internal medicine and in dentistry represents a promising field, as it could permit the development of innovative natural adjuvant therapies, able to empower the standard pharmaceutical therapies.
Keywords: 
Subject: Medicine and Pharmacology  -   Dietetics and Nutrition

1. Introduction

The pomegranate (Punica granatum L.) is a typical cultivation of Asian and Mediterranean countries and of Middle East and some USA areas [1,2]. Pomegranate fruit is composed of about 80% of water, 15% of carbohydrates, mainly sugars (like fructose, sucrose and glucose), and the remaining part is represented by fibers, vitamins (like vitamin C) and natural bioactive compounds (NBCs), namely polyphenols [3].
Although the pomegranate is present in our territories since ancient times, the data of the Italian “Istituto Nazionale di Statistica” (ISTAT) show that until 10 years ago this kind of crop was uncommon in Italy [4]. Initially, pomegranate was considered a simple ornamental plant, while now it has registered a growing trend in its consumption and this is due to the healthy properties emerged from numerous scientific studies that have highlighted the antioxidant and anti-radical activities of this “superfood”. Thanks to the high content of NBCs, the consumption of pomegranate appears to exert significative beneficial effects on human health, allowing to strengthen the immune system and to counteract the free radicals formation, responsible for many pathophysiological processes [5].
According to Aviram et al [6], it is estimated that in 1 kg of pomegranate, about 40% is represented by juice, while the components discarded amount up to 60%. Of the latter, the 50% is represented by mesocarp, endocarp and exocarp, while the 10% is represented by the seeds of the arils. These matrices, considered wastes from the agro-industrial sector, if properly managed, represent a precious resource, as they are a source of bioactive polyphenolic molecules, such as flavonoids, anthocyanins, tannins and in particular ellagitannins (like punicalagina) [1,7-9]. These compounds have been identified using various analytical techniques of liquid chromatography-mass spectrometry (LC-MS), like the liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the liquid chromatography-high-resolution-mass spectrometry (LC-HR-MS) [10,11]. In recent years, the use of LC-HR-MS instrumentation is increased rapidly for the qualitative identification of polyphenolic compounds present in plant matrices, such as the cultivation object of this work, which is particularly rich in ellagitannins.
The chemical composition of pomegranate differs, based on the variety and cultivation conditions. The peel, comprising 50% of the fruit's weight, is rich in phenolic compounds, such as phenolic acids, flavonoids and tannins. Flavonoids, notably anthocyanins in arils, contribute to the red colour and offer antimicrobial and antioxidant properties. Pomegranate components, including tannins, punicalagin, punicalin, strictinin A and granatin B, inhibit nitric oxide production and suppress inflammatory cytokine expression, due to ellagic acid (EA) action [12].
This review focuses on the biological activities of the bioactive polyphenolic compounds present in pomegranate and on the possible beneficial effects of these compounds in internal medicine and dentistry.

2. Materials and Methods

The purpose of this review is to analyze the scientific articles that put in evidence the possible positive and protective role of pomegranate in internal medicine and in dentistry. A literature search was conducted using three online databases, such as PubMed, Scopus and Cochrane Library.
The search was limited to peer-reviewed journals written in the English language and the search terms were “pomegranate” in combination with “internal medicine” AND “diabetes mellitus” AND “metabolic syndrome” AND “arterial hypertension” AND “dyslipidemia” AND “cancer” AND “bowel inflammatory diseases” AND “nephrolithiasis” AND “neurodegenerative disorders” AND “urinary tract infections” and pomegranate” in combination with “oral health”. The full search was manually retrieved.

3. Bioactive Polyphenolic Compounds of Pomegranate and Their Biological Activities

Pomegranate is rich in bioactive polyphenolic compounds, which exert numerous biological activities, demonstrated by several in vitro and in vivo studies (Figure 1).
Among the polyphenolic classes of pomegranate, there are Ellagitannins. They belong to the subclass of hydrolysable tannins and represent one of the most diverse groups of polyphenols derived from plant matrix, as they comprise over 1,000 identified NBCs [13]. Tannins, in general, exert a function of defense for the plant against attack by pathogens and herbivores. In fact, these compounds, including ellagitannins, are found in the vacuoles and in the cytoplasm of plant cells and play an important protective role in natural growth conditions [14]. Furthermore, these compounds, with strong astringent properties, are capable of complexing proteins and polysaccharides [15], they have a molecular weight between 300 and 20,000 Da and are found in the form of monomers (C-glycosidic ellagitannins with an open chain glucose portion), oligomers and complex tannins [15,16] but all these molecules have in common the presence in the chemical structure of at least one HHDP unit esterified in a polyol, generally glucose or quinic acid [17]. Several antimicrobial and antiviral properties are recognized in this subclass [18-21] that exert also beneficial effects in the prevention of chronic non-communicable diseases [13,18-22].
To have a complete picture of their use in the biomedical field, scientific studies have also taken into account the bioavailability of these molecules, characterized by a complex structure that does not permit their absorption from the gut microflora [23,24]. Their effect can be attributed to the fact that these compounds undergo a hydrolysis process in the digestive system, which transforms ellagitannins into smaller and less complex compounds, such as EA and urolithin, whose main effect on human health is attributable to the antioxidant and antiradical capacity. These molecules are able to counteract the action of free radicals and reactive oxygen species (ROS) [25].
The main bioactive compound present in pomegranate wastes is punicalagin [26,27], which, like the various polyphenolic compounds present in plant matrices, shows to have numerous biological and functional properties: antioxidant [20,28], antiviral [28] anti-inflammatory [29,30], antidiabetic [31], anticancer [32-34], cardio-protective [35-37] and antimicrobial [38-43].
The punicalagin is part of the subclass of ellagitannin and is the most representative compound within the pomegranate waste, in fact it represents about 70% of the total ellagitannins in the peel of the fruit. Punicalagin (C48H28O30) is a water-soluble polyphenolic compound, with a high degree of hydroxylation and high molecular weight, equal to 1084.7 Da. This compound is naturally found in the forms of two α and β reversible anomers [10,44-46].
Another of the most representative compounds in pomegranate fruit is EA (C14H6O8), which is a dimeric derivative of gallic acid (C7H6O5) [47]. EA is a thermostable molecule with a melting point of 350.3 C and a molecular weight of 302.19 g/mol, which is chemically identified as 2,3,7,8-tetrahydroxy-chromium [5,4,3-cde]chromene-5,10-Dione [21]. EA is a naturally occurring bioactive polyphenolic compound that is a secondary metabolite in many plant matrices.
This compound, identified as a dilatton of hexahydroxydiphenic acid (HHDP), showed beneficial effects in in vitro and in vivo models and it is characterized by a high free radical scavenging activity, as reported by Fischer et al. [27].
In addition to the antiradical ability, this compound has attracted particular attention from the scientific world in consideration of its antioxidant, anti-inflammatory, antimutagenic, antiproliferative, cardioprotective, hepatoprotective, nephroprotective and neuroprotective properties.
Both compounds most present in pomegranate wastes, such as punicalamine and EA, show to have an inhibitory activity of α-glucosidase [48], while another compound present in pomegranate wastes, in lower amounts, is gallic acid (GA).
Individual samples of pomegranate extracts can give different responses in tests for the evaluation of functional and biological activities and properties. This is due to the fact that these properties are related to the content of the polyphenolic compounds in the extracts, which can vary depending on the cultivars, as well as on the extraction procedures [40,49].
Furthermore, some scientific studies have compared the antioxidant activity in vitro on cell lines of single analytical standard of punicalagin and EA and of Punica granatum L. extracts. The authors demonstrated a superior bioactivity of the latter [20] and this evidence confirms, as highlighted in tests relative to other vegetal matrices, that the phytocomplex has a greater effectiveness, compared to the purified standard.

4. Sustainable Application of a Circular Economy Model for Pomegranate Wastes Recovery

In recent years, scientific evidences have led to an increased demand for sustainable products with remarkable healthy properties, highlighting the need to recover polyphenolic compounds. The latter origin from waste matrices in order to promote the sustainability goals, through the application of circular economy principles based on "zero waste” concept. Waste materials coming from pomegranate cultivation and mainly consist of plant tissues, such as exocarp, mesocarp, endocarp and seeds found in the arils.
Literature data showed that pomegranate wastes present biological activities ; among these, there are antioxidant, anti-inflammatory, antiproliferative and antimicrobial ones. For this purpose, the recovery models of pomegranate peel through the integration of extraction and purification phases, during the transformation processes, have been developed. These processes aim to obtain concentrated fractions rich in hydrolysable tannins as active principles for various purposes. In fact, these compounds can be used primarily as food additives, secondarily as functional foods ingredients, useful in the formulation and in the prototipation of products, bound to different markets [50-53].
Moreover, as for pomegranate, as well as for other plant matrices, it is possible to use dried and micronized wastes, in order to avoid the extraction process [54].
Beyond the primary utilization of high-quality fruits in the fresh market, the cultivation of Punica granatum L. can involve various processes. These include the innovative production of arils through a functional green withering, the production of juices obtained through cold pasteurization, as well as concentrates or innovative based gels, and finally, the production of depleted seed oil and/or flours for feed and food use. An appropriate dried process of fresh peels can lead to the production of powders such as micronized, natural pigmenting principles and standardized phyto-complexes in the hydrolysable tannin content, extending up to the energy production (Figure 2).

5. Pomegranate in Internal Medicine

The bioactive polyphenolic compounds of pomegranate are able to exert numerous beneficial properties useful in internal medicine (Figure 3).

5.1. Metabolic Syndrome

Metabolic syndrome (MetS) is a chronic pathology, characterized by the concomitant presence of at least three of the following conditions: i) abdominal obesity, ii) alteration of glucose metabolism, iii) arterial hypertension (AH), iv) low high-density lipoprotein (HDL) cholesterols and iv) hypertriglyceridemia. These conditions contribute to the onset of a low-grade inflammatory state and oxidative stress, typical of this syndrome [55]. The risk factors of MetS can be both genetic and environmental; the latter are often related to incorrect lifestyles, such as poor or no physical activity and unhealthy eating habits [56]. In recent years, the use of functional foods or oral food supplements, based on NBCs, has become relevant for the clinical management of MetS patients [57] and currently it represents an adjuvant therapy to be associated with traditional pharmacological treatments [55,58,59].
Some different pomegranate extracts, such as peels, flowers, juice and seeds are able to regulate the lipid metabolism, as confirmed by some in vivo studies [60]. In fact, a study conducted on hypercholesterolemic mouse models nourished with feed supplemented by 15% of pomegranate seed oil (PSO), for 28 days, highlighted a decrease in the plasma levels of triglyceride, total cholesterol and low-density lipoprotein (LDL) cholesterols, compared to the control group. This lipid-lowering effect was already highlighted by a previous study conducted on hypercholesterolemic type 2 diabetes mellitus (T2DM) patients, in which the supplementation of concentrated pomegranate juice (PJ), for 8 weeks, was able to reduce the atherogenic indices, like LDL-cholesterol/HDL-cholesterol and cholesterol total/HDL cholesterol [61]. Moreover, in a following study, conducted on 23 MetS women, it was investigated the possible effect of the daily consumption of 300 ml of PJ, for 6 weeks, on lipid peroxidation and on phospholipid fatty acid composition of plasma and erythrocytes. The authors highlighted a significant decrease of arachidonic acid and an increase of mono-unsaturated fatty acids in the erythrocyte membrane. They also showed a decrease of lipid peroxidation, evaluated by the reduction of levels of thiobarbituric acid reactive substances in erythrocytes, in the treatment subjects compared to control group. These results suggest a potential antioxidant, anti-inflammatory and cardio-protective action of pomegranate in dyslipidemic patients [62].
Further studies have demonstrated the effectiveness of pomegranate fruit in the treatment of T2DM, as it contains fiber, minerals, vitamins and other NBCs useful in glycemic control [63]. In this context, in vitro studies have demonstrated the anti-diabetic effects of pomegranate extracts, exerted through the stimulation of the peroxisome proliferator-activated receptor (PPAR)-γ, a transcription factor involved in glucose metabolism. [64]. Furthermore, PJ, rich in punicalagin, seems to be able to stimulate the release of insulin by β-cells, suggesting its potential role as an adjuvant treatment also in anti-diabetic therapy [65]. To support these hypotheses, a study conducted by Hashemy et al. described the beneficial effects of the pomegranate seeds powder assumption, at the dose of 5 g, twice per day, for 8 weeks, in T2DM patients. At the end of the study, the treated group showed a signifycant reduction of fasting blood glucose and glycated hemoglobin levels, compared to control group, suggesting how pomegranate can be used to control glycaemia in diabetic patients [66].
The bioactive polyphenolic compounds of pomegranate appear to play a crucial role also in reducing the body weight and improving the body composition in overweight or obese subjects [67,68]. In fact, a study conducted on obese non-diabetic premenopausal female patients, who daily assumed 300 mg of PSO, for 16 weeks, showed a significant reduction in body weight, waist circumference and liver fat content, as well as in serum triglycerides and C-reactive protein (CRP) levels, of treated women compared to control group [69].
Regarding the blood pressure, pomegranate has also proven useful in counteract AH, thanks to their anti-oxidative polyphenolic compounds. To confirm this, a single-blind placebo controlled randomized study, conducted on 60 T2DM patients, who have assumed 200 ml/day of PJ, for 6 weeks, highlighted a significant reduction in systolic and diastolic blood pressure, compared to control group [70].
Finally, pomegranate seems useful for counteracting the oxidative stress and the chronic low-grade inflammatory state, typical of MetS. In fact, in a study by Hossein et al., the authors described the beneficial effect of an oral food supplement (OFS) based on pomegranate, on inflammatory and oxidative stress biomarkers in overweight and obese individuals. In particular, 40 obese and overweight subjects have assumed 1000 mg of pomegranate extract daily, for 30 days. The pomegranate extract has significantly reduced interleukin (IL)-6 and high-sensitivity CRP levels, as well as the total cholesterol, glucose and insulin serum levels. This might suggest that pomegranate OFS may reduce those complications related to obesity, like low-grade chronic systemic inflammation [71].

5.2. Cancer

According to the current National Cancer Institute (NCI) definition, “cancer is a disease, in which some of the body’s cells grow uncontrollably and spread to other parts of the body” [72]. Cancer was conceptualized as a disease of genetic origin, however the research, over the last several decades, has established how environmental factors with epigenetic effects play a pivotal role in the phenomenon of carcinogenesis [73]. These environmental factors, capable of altering the spatial conformation of chromatin to regulate gene expression, include unhealthy nutrition, chemicals and industrial pollutants and poor lifestyle [74] (such as smoking, alcohol consumption and physical inactivity) [75]. However, while an unbalance diet, such as the Western Diet, increases the risk of cancer onset, on the other hand a balance diet, rich in fruit and vegetables, such as the Mediterranean Diet (MD), is an important factor in cancer prevention [76,77]. MD, thanks to the ability to guarantee a wide variety of micronutrients and other NBCs, is able to counteract the cancer [78,79]. Among NBCs are certainly included polyphenolic molecules, of which the pomegranate is rich. These molecules are capable to exert chemo-preventive and chemotherapeutic effects through their antioxidant, anti-radical and anti-inflammatory activities and through anti-mutagenic and anti-proliferative properties. The latter include the induction of apoptosis in cancer cells, the stimulation of the immune system [80,81], the modulation of hormonal concentration and metabolism, the cell cycle arrest, the enzymatic detoxification, the activation of transcription factors and the induction of apoptosis, the cell adhesion and finally, the production of growth factors against different type of cancer, such as breast cancer (BC), lung cancer (LC), colorectal cancer (CRC) and prostate cancer (PC) [82].

5.2.1. Pomegranate and Breast Cancer

BC, generally categorized into estrogen receptor (ER)-positive and ER-negative, is the most diagnosed cancer and the major cause of cancer-related death among females [83]. Many exogenous and endogenous risk factors could affect the onset and development of BC [84]. Among exogenous factors include early menarche, nulliparity, oral contraceptive use, never having or short duration of breast feeding, use of hormone replacement therapy, circadian disruption and unhealthy lifestyle (including smoking, alcohol consumption, imbalanced diet, etc). Endogenous risk factors, namely genetic factors, such as mutations on breast cancer gene 1 (BRCA1) and BRCA2, only account for approximately 5-10% of all BC incidences. For this reason, a possible strategy, capable to counteract the breast cancer carcinogenesis would be to modify the lifestyle and the nutritional choices, in order to guarantee a proper prevention for this type of cancer. Several in vitro studies have highlighted how pomegranate by-products, namely pomegranate fruit extract (PFE), PJ and PSO, are able to take part in the process of breast carcinogenesis, exhibiting the following effects: (i) the anti-proliferative, anti-aromatase and anti-estrogenic activities [85]; (ii) the regulation of the transforming growth factor beta (TGF-ß)/Smads pathway [86]; (iii) the anti-inflammatory effects, through the reduction of pro-inflammatory cytokines and chemokines; (iv) the reduction of vascular endothelial growth factor (VEGF) levels [87]; (v) the downregulation of the expression of the genes, involved in the damage of DNA and the estrogen-responsive genes [88]; (vi) and the disruption of ER and Wnt/ß-catenin signaling pathways [89].

5.2.2. Pomegranate and Lung Cancer

LC is the most common cancer and the leading cause of death worldwide, due to its diagnosis at an advanced stage [90]. In addition to a positive family history of LC, other important risk factors for this type of disease are tobacco smoking, unhealthy eating habits (such as high intake of fried or well-cooked red meat and alcohol consumption), chronic inflammation related to infections, exposure to ionizing radiations, occupational exposures (such as asbestos and indoor air pollution) [91]. Thanks to their countless nutrients, such as vitamins, minerals, phytochemicals and dietary fibers, fruits could play a pivotal role in the prevention of LC and in the risk reduction in current smokers, thanks to the ability of these micronutrients to exert antioxidant activities, to repair DNA from the oxidative damage, to inhibit tumor cell proliferation and to induce tumor cell apoptosis, caused by smoking [92]. It was highlighted how pomegranate polyphenols have potent chemotherapeutic properties that exert anti-cancerous activities on lung carcinoma. In more detail, several in vitro studies have pointed out how pomegranate leaf extract (PLE) have potential anti-proliferative, antimigratory [93] and anti-metastasis properties against the lung carcinoma, while pomegranate peel extract (PPE), PJ and PSO, tested both in vitro and in vivo studies, have shown strong anti-inflammatory activities, reducing the proinflammatory cytokine levels (IL-1β and IL-6), and strong antioxidant properties inactivating cellular oxygen radicals in the lungs [94]. In addition to the effects described above, PFE seems to play a pivotal role against the LC. In fact, both in vitro and in vivo studies have shown how PFE is involved in the downregulation and the inhibition of several signaling pathways against lung cancerous cells, including NF-κB expression, MAPK phosphorylation, PI3K and mTOR pathway activity and Akt phosphorylation, leading to reduced cell proliferation and angiogenesis in lungs [95,96].

5.2.3. Pomegranate and Colon Cancer

CRC is the third most common cancer and the fourth most frequent cause of cancer deaths worldwide. Several risk factors are thought to contribute to its etiopathogenesis such as older age, genetic and environment, including a diet rich in meat and fats and poor in fibers, folate and calcium, a sedentary lifestyle, obesity, high alcohol intake, smoking, etc. [97]. It is well known through several clinical studies how a highly rich fibers diet based on computation of plant-based foods, such as fruits and vegetables, is a protective factor, associated with a decrease in CRC incidence [98]. Dietary fiber is composed by plant-based carbohydrates that cannot be metabolized by digestive enzymes encoded in the human genome, such as amylase. However, this macronutrient, through an anaerobic fermentation process, can be metabolized by certain species of gut microbiota, producing short chain fatty acids (SCFAs) which include acetate, propionate and butyrate [99]. It has been shown that the latter may have anti-neoplastic properties in colon, modulating the immune response, thereby resulting in protection against CRC [100]. Moreover, the production of the SCFAs reduces the colonic pH, preventing the conversion of bile acid metabolites into more toxic forms [101].
As well as being rich in vitamins, such as vitamin A, E, C, B1 and B2, minerals and phytochemicals, namely polyphenolic compounds, the pomegranate micronized peel is a rich reservoir of dietary fiber. Thereby, it represents a byproduct useful in the CRC prevention, thanks to its remarkable bioactivity [102]. It is also worth emphasizing how gut microbiota plays a crucial role in the polyphenols catabolism. Indeed, when colon bacteria degrade dietary fiber, the ellagitannins, obtained from pomegranate, are hydrolyzed to form EA and are transformed into urolithin by gut microbiota. Thus, these compounds exert their action in the prevention of CRC carcinogenesis, by remodeling gut microbiota [103]. Furthermore, the consumption of PJ is capable to release ellagitannins and urolithins in the colon, potentially reducing the risk of CRC development, by inhibiting cell proliferation and inducing apoptosis [104]. Several studies have also highlighted how PJ plays an important role in the downregulation of the inflammatory signaling pathways in colon cancer cells through the inhibition of cyclooxygenase-2 (COX-2) expression [22,105]. The activity of this enzyme is increased in many cancers, such as CRC [106]. Moreover, PJ suppresses the Akt activation, needed for NF-κB DNA binding. Finally, several in vitro studies have emphasized the PJ anti-proliferative and pro-apoptotic effects against CRC cells [22]. As regards the PSO, in vivo studies have shown how its consumption is significantly correlated with the inhibition of the colon tumorigenesis, due to the up-regulation of the PPARγ protein expression in the rats colon [107].

5.2.4. Pomegranate and Prostate Cancer

PC is the second most common form of cancer in men [108]. Non-modifiable risk factors for PC include age, the genetic predisposition and the ethnicity, while modifiable risk factors include environmental factors, such as obesity, smoking, low physical exercise and unhealthy diet that play a pivotal role in the initiation, in the promotion and in the progression of PC. In fact, several studies have highlighted how an excessive intake of sutured fats from dairy products and ultraprocessed meat is associated with an increased risk of PC [109,110]. As for other types of cancer, a considerable amount of in vitro and in vivo studies has shown how PJ and PE possess anti-proliferative, proapoptotic and anti-metastatic actions, decreasing the levels of pro-inflammatory cytokines and chemokines and inhibiting the angiogenesis through the reduction of VEGF levels [111]. Moreover, these compounds are capable to act on the canonical signaling pathways, namely NF-kB and PI3K/Akt/mTOR in human PC cell lines and/or in mouse PC tumor models [112,113]. Moreover, the possible chemopreventive and chemotherapeutic effects exhibited by the ellagitannins contained in PJ and PE against PC, have also been found, both in vivo and in vitro studies. These studies demonstrated a reduction in the expression of androgen genes, that play a crucial role in the PC cell growth and progression [114]. Several studies have highlighted the association of PC and gut microbiota dysbiosis, suggesting that the latter might be involved in not only gastrointestinal cancers (GC) but also in PC. In fact, it could exist a “microbiota-gut-prostate axis” so that the pro-inflammatory cytokines and the pathogen bacteria of the gut microbiota enter in the systemic circulation, thanks to the increased permeability of the gastrointestinal tract barrier and to the altered tight-junctions. These alterations seem to be induced by gut microbiota dysbiosis and local inflammation, suggesting the potential role of the diet on PC [115]. Different in vivo studies have focused the attention on how PPE reshapes the gut microbiota thanks to its countless properties, exert by phytochemicals compounds contained therein, and thus costituting a possible adjuvant therapy for PC [116].

5.3. Urinary Tract Infections

Pomegranate exerts antimicrobial effects against the main pathogens that cause urinary tract infections (UTIs) [117]. In particular, it would seem that every part of the pomegranate plant has antimicrobial activity, suggesting that pomegranate-based OFSs can counteract UTIs. OFSs can also be formulated starting from wastes of the pomegranate supply chain [118]. An interesting study investigated the antimicrobial activity of 17 medicinal plants, in extracts of water, acetone and ethanol, against the main pathogens causing UTIs, highlighting how pomegranate ethanol extract shows a strong antibacterial activity against Escherichia coli [119]. Among the numerous phytochemical compounds of pomegranate, those that have shown the highest antimicrobial activity are the EA and the hydrolyzable tannins, such as punicalagin. In most studies, their combination showed the greatest benefits [118].

5.4. Nephrolithiasis

Numerous studies have highlighted a direct correlation between oxidative stress and nephrolithiasis, although the mechanism underlying the increased kidney stones development in presence of oxidative stress hasn’t been well defined yet [120]. In this context, PJ, which has been shown to exert important antioxidant scavenging actions against ROS, could represent a valid adjuvant strategy in the prevention of stone formation [121]. An in vitro study, conducted on tissues from murine models, observed a reduction in crystal deposits in the renal tubules in mice fed PJ, compared to the control group [122]. Subsequently, Tracy et al. have developed a clinical trial conducted on patients suffering from recurrent kidney stones, who had been administered a pomegranate polyphenolic extract, at a concentration of 1,000 mg/day, for 90 days. The authors highlighted how patients suffering from recurrent kidney stones had high levels of oxidative stress and how the consumption of pomegranate polyphenols significantly reduced the oxidative stress itself and induced a trend in the calcium oxalate saturation levels reduction [121]. Although these results are promising, they would be further investigated to confirm the beneficial role of pomegranate against nephrolithiasis, because the data to support this thesis are not sufficient, currently.

5.5. Inflammatory Bowel Diseases

Inflammatory bowel diseases (IBDs) are described as chronic diseases characterized by recurrent inflammation of the intestinal tract with multifactorial genesis, in which autoimmune, genetic and environmental factors are involved. IBDs include Crohn's disease and ulcerative colitis [123]. Numerous scientific evidences highlight how a diet rich in polyphenols seems to play a key role in mitigating the chronic inflammation, underlying IBDs [124]. A study conducted on murine models evaluated the effect of a treatment with PJ, containing ellagitannins and EA, in mice with colitis and colon ulceration, emphasizing how PJ is able to reduce the expression of pro-inflammatory cytokines, like tumor necrosis factor (TNF)-α and IL-1β and of COX-2. Furthermore, the gut microbiota of mice treated with PJ at the end of the study showed an increase in Ruminococcaceae, butyrate-producing bacteria [124].
IBDs are characterized by the inflammation of the colon mucosa, accompanied by the infiltration of inflammatory cells, including neutrophils, which represent the defense first line of the immune system and which produce a series of inflammatory molecules [125]. A randomized controlled trial, conducted on a group of IBDs patients, with a high rate of relapses, evaluated the effects of supplementation with PJ, rich in ellagitannins, in the modulation of local and systemic inflammation biomarkers. The authors examined whether patients treated with PJ for 12 weeks showed a reduction in the fecal concentration of calprotectin (a protein derived from fecal neutrophils, marker of inflammation of the intestinal mucosa) and in the serum concentration of CRP, erythrocyte sedimentation rate (ESR), TNF-α and IL-6, markers of systemic inflammation [126].
Furthermore, in this context, it has been demonstrated that the pomegranate peel polyphenols appear to be able to reduce gut permeability to inflammatory cells, induced by lipopolysaccharide (LPS), suggesting that wastes from the pomegranate agri-food chain could also be used as effective anti-inflammatory agents in the IBDs treatment [127].
Finally, pomegranate seems to exert a protective role against IBDs in the acute phase. In fact, in murine models with ulcerative colitis in the acute phase, the EA supplementation appears to ameliorate the severity of the disease, both through the improvement of colon ulcerations and through the reduction of the inflammatory profile [128].

5.6. Neurodegenerative Diseases

PJ would seem able to attenuate the neuro-inflammation suggesting that this fruit can be useful in counteracting the onset and the symptoms of age-associated neurodegenerative pathologies, such as Alzheimer's and Parkinson’s diseases [128]. Pomegranate polyphenolic compounds reduce the neuro-inflammation by several mechanisms, which include: (i) the inhibition of NF-κB, a transcription factor involved in the inflammatory process [129]; (ii) the reduction of the pro-inflammatory cytokines, such as IL-2, IL-6, IL-1β and TNF-α [130]; (iii) the reduction of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) gene expression, responsible for the production and the deposition of the β-amyloid peptide, involved in Alzheimer's disease; (iv) the reduction of COX-2 activity [131]; (v) the reduction of the catalytic activity of caspases [132].
Pomegranate polyphenols seem able to improve the synaptic function during Alzheimer's disease. In fact, a study conducted on mouse models subjected to nutritional supplementation with pomegranate extracts (4% w/w) for 15 months, highlighted a protective role of pomegranate against the proteins that improve the synaptic structure, such as synaptophysin, PSD-95, Munc18-1 and SNAP25 [133].
Finally, the supplementation with pomegranate extracts (4% w/w) would seem to protect the brain from oxidative damage in mouse models affected by Alzheimer's, through the reduction of lipid peroxidation (LPO) and carbonyl levels and the restoration of the antioxidant enzymes activities, like glutathione peroxidase, superoxide dismutase (SOD) and glutathione S-transferase (GST) [134].
Although clinical studies on humans are lacking, in vitro and on animal models studies seem encouraging and suggest that pomegranate and its phenolic compounds possess important anti-inflammatory and neuroprotective properties that could be effective against the symptoms of neurodegenerative diseases with neuro-inflammatory etiopathology [135].

6. Pomegranate and Oral Health

Pomegranate has garnered a significant attention in the field of dentistry for its potential therapeutic properties, particularly in the treatment of dental plaque, gingivitis and periodontitis. The literature data about this fruit have revealed a multitude of benefits, making it a valuable candidate to promote oral health.
Dental plaque, a biofilm of bacteria that forms on tooth surfaces, is a primary contributor to oral health problems. Pomegranate has been studied extensively for its ability to counteract the dental plaque formation. The flavonoids present in pomegranate demonstrated a robust antibacterial action against key contributors to the plaque formation, including Streptococcus sanguis and Eikenella corrodens [136,137]. Its antibacterial effect is attributed to tannins, compounds that enhance bacteriolysis and impair the bacterial adherence to tooth surfaces. Comparative studies have highlighted the pomegranate's superior inhibition capacity towards specific bacteria, compared to chlorhexidine (CHX), a commonly used oral antiseptic [138]. Despite limited research about pomegranate's impact on plaque and on salivary proteins, a study conducted on adolescents revealed that pomegranate mouthrinse significantly reduced plaque accumulation and gingivitis, compared to a placebo. This finding aligns with existing literature, suggesting pomegranate extract's potentiality as an adjunct therapy for treating gingivitis with minimal side effects [139].
Moreover, pomegranate mouthwash has proven to be effective against periodontal pathogens, such as Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and Prevotella intermedia [140]. Notably, pomegranate's role in inhibiting quorum sensing in bacteria, a process vital for gene expression related to antibiotic resistance and to biofilm development. This pomegranate function adds an intriguing dimension to its antibacterial properties [141,142].
Orthodontic patients, who often face challenges in maintaining oral hygiene, have benefited from a hydro-alcoholic extract of pomegranate, demonstrating a substantial reduction in dental plaque bacteria, compared to CHX [143]. The ellagitannin punicalagin has been identified as a key contributor to pomegranate's antibacterial activity [20].
Beyond its antibacterial prowess, pomegranate exhibits a positive synergistic effect with antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive S. aureus, showcasing its potentiality as a complementary agent in the battle against antibiotic-resistant strains [144].
Gingivitis is characterized by chronic inflammation and early clinical manifestations like gum bleeding [145-147]. This oral ailment leads to increased salivary albumin, cystatin C and amylase. The enhancement of the latter is due to plasma protein leakage into the gingival crevicular fluid, thus offering a non-invasive diagnostic tool.
Clinical studies affirm pomegranate efficacy in reducing gingival bleeding and in diminishing colony-forming units (CFUs) of dental plaque organisms [148,149]. Mouthrinse containing pomegranate extract has also demonstrated effective in reducing bacterial protein levels and activities related to cell injury, increasing the antioxidant enzymes activity, thus highlighting its potential role in oral health maintenance [118,150].
For periodontitis, studies emphasize pomegranate's anti-inflammatory effects and its potentiality as adjuvant treatment to the conventional periodontal therapy [151]. Biochemical investigations reveal significant decreases in inflammatory markers (IL-1β and IL-6), indicating pomegranate potentiality in managing periodontal disease [152].
Pomegranate also enhances the growth of enteric probiotic bacteria, suggesting potential benefits in decreasing the periodontal pathogen load [153]. Its antibacterial activity extends to Helicobacter pylori, associated with deep periodontal pockets. While, its anti-viral properties may contribute to treat the periodontitis triggered by viral infections [154,155].
For chronic periodontitis, pomegranate-based compounds have also proven effective. In fact, clinical studies have demonstrated the effectiveness of pomegranate extract in reducing the inflammation in this chronic condition, inhibiting the periodontopathogens. Moreover, it has shown its action against microbial growth, including the growth inhibition of S. aureus and of MRSA strains [148,156-158].
Pomegranate's applications extend even further. It has demonstrated the ability in treating recurrent aphthous stomatitis, promoting wound healing and acting as a medium storage for avulsed teeth [159-161]. Its several applications grant pomegranate to become a promising candidate for various oral health issues.
An optimal therapeutic agent for plaque control must fulfill selected criteria, including specificity for plaque bacteria, substantivity, stability, lack of adverse reactions, toxic safety, ecological safety and user-friendly features [162]. Pomegranate seems to well align with these criteria [12].
Research supporting pomegranate's role in oral health is primarily limited to in vitro studies, although promising in vivo studies exist. Pomegranate rinsing reduces α-glucosidase activity and increases ceruloplasmin activity in saliva [12]. Pomegranate extract effectively treats denture stomatitis, associated with candidiasis [163]. Pomegranate tannins inhibit human salivary α-amylase, a substrate for cariogenic microbes [164,165]. Studies on periodontal therapy support the efficacy of a gel containing extracts of Centella asiatica and Punica granatum [152]. Chewing pomegranate seems to enhance antibacterial and antioxidant effects and to boost salivary flow rate. Pomegranate flower extract inhibits the bacterial sucrose-digesting enzyme linked to dental caries and gingivitis [166]. Antioxidant agents from pomegranate are hypothesized to have preventive effects against oral cavity diseases [167]. Pomegranate extracts reduce aspartate aminotransferase activities, suggesting benefits in periodontal pathology [168]. Hydroalcoholic extracts from pomegranate fruit significantly decrease dental plaque CFUs, offering an alternative for reducing plaque bacteria [143]. Pomegranate contributes to the maintaining of the oral hygiene and reduces microorganisms cultured from dental plaque in one-minute rinses with a mouthwash containing pomegranate extract [150].
Punicic acid in PSO acts as an anti-inflammatory agent by down-regulating neutrophil activation and LPO [169,170].
Tooth decay, initiated by Streptococcus mutans in the oral cavity, is a prevalent chronic condition, affecting children and young adults. Conventional mouthwashes, like CHX, possess antimicrobial properties but are also associated with drawbacks, such as staining and taste alterations. A recent study explores the antibacterial potentiality of pomegranate peel and guava leaves extracts, comparing them with CHX in a group of children. The results indicate a significant reduction (p < 0.01) in S. mutans count after using pomegranate and guava leaves extracts. The beneficial effects seem to be directly correlated with the concentration of these extracts. However, the efficacy of CHX outperformed both extracts, emphasizing the need for further research on combined antimicrobial approach [171]. In fact, CHX is the gold standard for its potent antibacterial and antiplaque properties, but its use is associated with certain side effects. Among these, xerostomia (dry mouth), hypogeusia (reduced sense of taste) and discoloration of the tongue. In particular, long-term use of CHX may lead to the development of calculus on teeth and extrinsic tooth staining. In this contest, it is important to explore alternative oral care solutions with fewer associated side effects [172,173]. Among these, herbal products have been investigated, where the pomegranate seems to represent one of the most effective herbal remedies. At this regard, a study aimed to evaluate the ability of pomegranate mouthrinse compared to 0.12% CHX mouthrinse. In detail, this study examined the impact of these solutions on the reduction of bacterial plaque and the gingivitis, among individuals aged 18–25 years. The results demonstrated antiplaque and antigingivitis effects of both mouthrinses. In particular, pomegranate showed a superior antigingivitis power, but it did not match the antiplaque effectiveness of CHX. Although pomegranate mouthrinse represents a convenient and styptic option with acceptable plaque reduction, further clinical trials are warranted to establish its real action and its advantages over CHX, the current gold standard for the plaque control [174].

7. Conclusions

In conclusion, the extensive body of research on pomegranate in internal medicine and in dentistry, underscores its multifaceted benefits and its potential applications in addressing both for internal medicine chronic diseases and for various oral health concerns. From its robust anti-inflammatory, antioxidant, anti-cancerous and antibacterial properties, pomegranate emerges as a versatile and promising candidate in the prevention and in the treatment of diseases of internist relevance and in the oral care regimens. However, while the existing studies provide valuable insights, the need for further extensive clinical trials and long-term assessments is evident to establish its real effectiveness, safety and its advantages over conventional treatments. The ongoing exploration about pomegranate in internal medicine and in dentistry promises for the development of innovative and natural solutions, useful for the clinical management of several internal medical pathological conditions and of oral diseases.

Author Contributions

Conceptualization, G.M. and A.N.; writing—original draft preparation, G.M, M.B, M.D.L, C.V, C.M, F.K., K.C and G.Mad.; writing—review and editing, P.B., A.D and A.N.; visualization, G.M., M.D.L and C.V.; supervision, P.B., A.D and A.N. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We would like to thank Doctor Gabriella Venafro for English language revision.

Conflicts of Interest

The authors declare no conflicts of interest.

Disclaimer/Publisher’s Note

Not applicable.

References

  1. Ambigaipalan, P.; de Camargo, A.C.; Shahidi, F. Phenolic Compounds of Pomegranate Byproducts (Outer Skin, Mesocarp, Divider Membrane) and Their Antioxidant Activities. J Agric Food Chem 2016, 64, 6584–6604. [Google Scholar] [CrossRef]
  2. Liu, Y.; Seeram, N.P. Liquid chromatography coupled with time-of-flight tandem mass spectrometry for comprehensive phenolic characterization of pomegranate fruit and flower extracts used as ingredients in botanical dietary supplements. J Sep Sci 2018, 41, 3022–3033. [Google Scholar] [CrossRef]
  3. Vucic, V.; Grabez, M.; Trchounian, A.; Arsic, A. Composition and Potential Health Benefits of Pomegranate: A Review. Curr Pharm Des 2019, 25, 1817–1827. [Google Scholar] [CrossRef]
  4. ISTAT. Coltivazioni legnose fruttifere. Availabe online: http://dati.istat.it/index.aspx?queryid=33705# (accessed on 15 January).
  5. Zarfeshany, A.; Asgary, S.; Javanmard, S.H. Potent health effects of pomegranate. Adv Biomed Res 2014, 3, 100. [Google Scholar] [CrossRef]
  6. Aviram, M.; Dornfeld, L.; Rosenblat, M.; Volkova, N.; Kaplan, M.; Coleman, R.; Hayek, T.; Presser, D.; Fuhrman, B. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000, 71, 1062–1076. [Google Scholar] [CrossRef] [PubMed]
  7. Aguilar-Zarate, P.; Wong-Paz, J.E.; Michel, M.; Buenrostro-Figueroa, J.; Diaz, H.R.; Ascacio, J.A.; Contreras-Esquivel, J.C.; Gutierrez-Sanchez, G.; Aguilar, C.N. Characterisation of Pomegranate-Husk Polyphenols and Semi-Preparative Fractionation of Punicalagin. Phytochem Anal 2017, 28, 433–438. [Google Scholar] [CrossRef] [PubMed]
  8. Romani, A.; Campo, M.; Urciuoli, S.; Marrone, G.; Noce, A.; Bernini, R. An Industrial and Sustainable Platform for the Production of Bioactive Micronized Powders and Extracts Enriched in Polyphenols From Olea europaea L. and Vitis vinifera L. Wastes. Front Nutr 2020, 7, 120. [Google Scholar] [CrossRef] [PubMed]
  9. Yisimayili, Z.; Abdulla, R.; Tian, Q.; Wang, Y.; Chen, M.; Sun, Z.; Li, Z.; Liu, F.; Aisa, H.A.; Huang, C. A comprehensive study of pomegranate flowers polyphenols and metabolites in rat biological samples by high-performance liquid chromatography quadrupole time-of-flight mass spectrometry. Journal of Chromatography A 2019, 1604, 460472. [Google Scholar] [CrossRef]
  10. Barbieri, M.; Heard, C.M. Isolation of punicalagin from Punica granatum rind extract using mass-directed semi-preparative ESI-AP single quadrupole LC-MS. J Pharm Biomed Anal 2019, 166, 90–94. [Google Scholar] [CrossRef]
  11. Solakyildirim, K. Fast Punicalagin Content Analysis of Various Brands of Pomegranate (Punica granatum L.) Juices by UPLC-MS. Hacettepe Journal of Biology and Chemistry 2019, 47, 267–275. [Google Scholar] [CrossRef]
  12. Bielli, P.; Calabrese, L. Structure to function relationships in ceruloplasmin: a 'moonlighting' protein. Cell Mol Life Sci 2002, 59, 1413–1427. [Google Scholar] [CrossRef]
  13. Yamada, H.; Wakamori, S.; Hirokane, T.; Ikeuchi, K.; Matsumoto, S. Structural Revisions in Natural Ellagitannins. Molecules 2018, 23. [Google Scholar] [CrossRef] [PubMed]
  14. Barbehenn, R.V.; Peter Constabel, C. Tannins in plant–herbivore interactions. Phytochemistry 2011, 72, 1551–1565. [Google Scholar] [CrossRef] [PubMed]
  15. Yoshida, T.; Amakura, Y.; Yoshimura, M. Structural features and biological properties of ellagitannins in some plant families of the order Myrtales. Int J Mol Sci 2010, 11, 79–106. [Google Scholar] [CrossRef] [PubMed]
  16. Khanbabaee, K.; van Ree, T. Tannins: classification and definition. Nat Prod Rep 2001, 18, 641–649. [Google Scholar] [CrossRef]
  17. Clifford, M.N.; Scalbert, A. Ellagitannins – nature, occurrence and dietary burden. J Sci Food Agr 2000, 80, 1118–1125. [Google Scholar] [CrossRef]
  18. Castonguay, A.; Gali, H.; Perchellet, E.; Gao, X.; Boukharta, M.; Jalbert, G.; Okuda, T.; Yoshida, T.; Hatano, T.; Perchellet, J. Antitumorigenic and antipromoting activities of ellagic acid, ellagitannins and oligomeric anthocyanin and procyanidin. Int J Oncol 1997, 10, 367–373. [Google Scholar] [CrossRef] [PubMed]
  19. Quave, C.L.; Estevez-Carmona, M.; Compadre, C.M.; Hobby, G.; Hendrickson, H.; Beenken, K.E.; Smeltzer, M.S. Ellagic acid derivatives from Rubus ulmifolius inhibit Staphylococcus aureus biofilm formation and improve response to antibiotics. PLoS One 2012, 7, e28737. [Google Scholar] [CrossRef]
  20. Seeram, N.P.; Adams, L.S.; Henning, S.M.; Niu, Y.; Zhang, Y.; Nair, M.G.; Heber, D. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005, 16, 360–367. [Google Scholar] [CrossRef]
  21. Sharifi-Rad, J.; Quispe, C.; Castillo, C.M.S.; Caroca, R.; Lazo-Velez, M.A.; Antonyak, H.; Polishchuk, A.; Lysiuk, R.; Oliinyk, P.; De Masi, L. , et al. Ellagic Acid: A Review on Its Natural Sources, Chemical Stability, and Therapeutic Potential. Oxid Med Cell Longev 2022, 2022, 3848084. [Google Scholar] [CrossRef]
  22. Adams, L.S.; Seeram, N.P.; Aggarwal, B.B.; Takada, Y.; Sand, D.; Heber, D. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 2006, 54, 980–985. [Google Scholar] [CrossRef] [PubMed]
  23. Espin, J.C.; Garcia-Conesa, M.T.; Tomas-Barberan, F.A. Nutraceuticals: facts and fiction. Phytochemistry 2007, 68, 2986–3008. [Google Scholar] [CrossRef] [PubMed]
  24. Vora, A.K.; Londhe, V.Y.; Pandita, N.S. Preparation and characterization of standardized pomegranate extract-phospholipid complex as an effective drug delivery tool. J Adv Pharm Technol Res 2015, 6, 75–80. [Google Scholar] [CrossRef] [PubMed]
  25. Fraga-Corral, M.; Otero, P.; Cassani, L.; Echave, J.; Garcia-Oliveira, P.; Carpena, M.; Chamorro, F.; Lourenco-Lopes, C.; Prieto, M.A.; Simal-Gandara, J. Traditional Applications of Tannin Rich Extracts Supported by Scientific Data: Chemical Composition, Bioavailability and Bioaccessibility. Foods 2021, 10. [Google Scholar] [CrossRef] [PubMed]
  26. Khwairakpam, A.D.; Bordoloi, D.; Thakur, K.K.; Monisha, J.; Arfuso, F.; Sethi, G.; Mishra, S.; Kumar, A.P.; Kunnumakkara, A.B. Possible use of Punica granatum (Pomegranate) in cancer therapy. Pharmacol Res 2018, 133, 53–64. [Google Scholar] [CrossRef] [PubMed]
  27. Fischer, U.A.; Carle, R.; Kammerer, D.R. Identification and quantification of phenolic compounds from pomegranate (Punica granatum L.) peel, mesocarp, aril and differently produced juices by HPLC-DAD-ESI/MS(n). Food Chem 2011, 127, 807–821. [Google Scholar] [CrossRef] [PubMed]
  28. Abid, M.; Yaich, H.; Cheikhrouhou, S.; Khemakhem, I.; Bouaziz, M.; Attia, H.; Ayadi, M. Antioxidant properties and phenolic profile characterization by LC–MS/MS of selected Tunisian pomegranate peels. Journal of Food Science and Technology 2017, 54. [Google Scholar] [CrossRef]
  29. BenSaad, L.A.; Kim, K.H.; Quah, C.C.; Kim, W.R.; Shahimi, M. Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A&B isolated from Punica granatum. BMC Complementary and Alternative Medicine 2017, 17, 47. [Google Scholar] [CrossRef]
  30. Subkorn, P.; Norkaew, C.; Deesrisak, K.; Tanyong, D. Punicalagin, a pomegranate compound, induces apoptosis and autophagy in acute leukemia. PeerJ 2021, 9, e12303. [Google Scholar] [CrossRef]
  31. Abdulhadi, H.L.; Dabdoub, B.R.; Ali, L.H.; Othman, A.I.; Amer, M.E.; El-Missiry, M.A. Punicalagin protects against the development of pancreatic injury and insulitis in rats with induced T1DM by reducing inflammation and oxidative stress. Mol Cell Biochem 2022, 477, 2817–2828. [Google Scholar] [CrossRef]
  32. Cheng, X.; Yao, X.; Xu, S.; Pan, J.; Yu, H.; Bao, J.; Guan, H.; Lu, R.; Zhang, L. Punicalagin induces senescent growth arrest in human papillary thyroid carcinoma BCPAP cells via NF-kappaB signaling pathway. Biomed Pharmacother 2018, 103, 490–498. [Google Scholar] [CrossRef]
  33. Tamborlin, L.; Sumere, B.R.; de Souza, M.C.; Pestana, N.F.; Aguiar, A.C.; Eberlin, M.N.; Simabuco, F.M.; Rostagno, M.A.; Luchessi, A.D. Characterization of pomegranate peel extracts obtained using different solvents and their effects on cell cycle and apoptosis in leukemia cells. Food Sci Nutr 2020, 8, 5483–5496. [Google Scholar] [CrossRef] [PubMed]
  34. Berkoz, M.; Krosniak, M. Punicalagin induces apoptosis in A549 cell line through mitochondria-mediated pathway. Gen Physiol Biophys 2020, 39, 557–567. [Google Scholar] [CrossRef] [PubMed]
  35. Peng, J.F.; Zhao, X.N.; Zhang, M.; Li, J.Y.; Zhao, C.C.; Wang, S.S.; Wang, J.L.; Shi, H.; Zhou, P.; Wang, L. Punicalagin attenuates ventricular remodeling after acute myocardial infarction via regulating the NLRP3/caspase-1 pathway. Pharm Biol 2023, 61, 963–972. [Google Scholar] [CrossRef]
  36. Alexandre, E.M.C.; Silva, S.; Santos, S.A.O.; Silvestre, A.J.D.; Duarte, M.F.; Saraiva, J.A.; Pintado, M. Antimicrobial activity of pomegranate peel extracts performed by high pressure and enzymatic assisted extraction. Food Res Int 2019, 115, 167–176. [Google Scholar] [CrossRef]
  37. Gullon, P.; Astray, G.; Gullon, B.; Tomasevic, I.; Lorenzo, J.M. Pomegranate Peel as Suitable Source of High-Added Value Bioactives: Tailored Functionalized Meat Products. Molecules 2020, 25. [Google Scholar] [CrossRef]
  38. Singh, B.; Singh, J.P.; Kaur, A.; Singh, N. Antimicrobial potential of pomegranate peel: a review. International Journal of Food Science & Technology 2018, 54. [Google Scholar] [CrossRef]
  39. Negi, P.S. Plant extracts for the control of bacterial growth: efficacy, stability and safety issues for food application. Int J Food Microbiol 2012, 156, 7–17. [Google Scholar] [CrossRef] [PubMed]
  40. Smaoui, S.; Hlima, H.B.; Mtibaa, A.C.; Fourati, M.; Sellem, I.; Elhadef, K.; Ennouri, K.; Mellouli, L. Pomegranate peel as phenolic compounds source: Advanced analytical strategies and practical use in meat products. Meat Sci 2019, 158, 107914. [Google Scholar] [CrossRef]
  41. Trigo, J.P.; Alexandre, E.M.C.; Saraiva, J.A.; Pintado, M.E. High value-added compounds from fruit and vegetable by-products - Characterization, bioactivities, and application in the development of novel food products. Crit Rev Food Sci Nutr 2020, 60, 1388–1416. [Google Scholar] [CrossRef]
  42. Farha, A.K.; Yang, Q.-Q.; Kim, G.; Li, H.-B.; Zhu, F.; Liu, H.-Y.; Gan, R.-Y.; Corke, H. Tannins as an alternative to antibiotics. Food Bioscience 2020, 38, 100751. [Google Scholar] [CrossRef]
  43. Xu, Y.; Shi, C.; Wu, Q.; Zheng, Z.; Liu, P.; Li, G.; Peng, X.; Xia, X. Antimicrobial Activity of Punicalagin Against Staphylococcus aureus and Its Effect on Biofilm Formation. Foodborne Pathog Dis 2017, 14, 282–287. [Google Scholar] [CrossRef] [PubMed]
  44. Almowallad, S.; Huwait, E.; Al-Massabi, R.; Saddeek, S.; Gauthaman, K.; Prola, A. Punicalagin Regulates Key Processes Associated with Atherosclerosis in THP-1 Cellular Model. Pharmaceuticals (Basel) 2020, 13. [Google Scholar] [CrossRef] [PubMed]
  45. Giamogante, F.; Marrocco, I.; Cervoni, L.; Eufemi, M.; Chichiarelli, S.; Altieri, F. Punicalagin, an active pomegranate component, is a new inhibitor of PDIA3 reductase activity. Biochimie 2018, 147, 122–129. [Google Scholar] [CrossRef] [PubMed]
  46. Kazemi, M.; Karim, R.; Mirhosseini, H.; Abdul Hamid, A. Optimization of pulsed ultrasound-assisted technique for extraction of phenolics from pomegranate peel of Malas variety: Punicalagin and hydroxybenzoic acids. Food Chem 2016, 206, 156–166. [Google Scholar] [CrossRef] [PubMed]
  47. Jourdes, M.; Pouységu, L.; Quideau, S.; Mattivi, F.; Truchado, P.; Tomás-Barberán, F.A. Handbook of Analysis of Active Compounds in Functional Foods, 1st Edition ed.; Francis, C.P.T., Ed. CRC Press: United States, 2012. [Google Scholar]
  48. Bellesia, A.; Verzelloni, E.; Tagliazucchi, D. Pomegranate ellagitannins inhibit alpha-glucosidase activity in vitro and reduce starch digestibility under simulated gastro-intestinal conditions. Int J Food Sci Nutr 2015, 66, 85–92. [Google Scholar] [CrossRef] [PubMed]
  49. Garcia, P.; Fredes, C.; Cea, I.; Lozano-Sanchez, J.; Leyva-Jimenez, F.J.; Robert, P.; Vergara, C.; Jimenez, P. Recovery of Bioactive Compounds from Pomegranate (Punica granatum L.) Peel Using Pressurized Liquid Extraction. Foods 2021, 10. [Google Scholar] [CrossRef] [PubMed]
  50. Hasnaoui, N.; Wathelet, B.; Jimenez-Araujo, A. Valorization of pomegranate peel from 12 cultivars: dietary fibre composition, antioxidant capacity and functional properties. Food Chem 2014, 160, 196–203. [Google Scholar] [CrossRef] [PubMed]
  51. Imperatori, F.; Barlozzari, G.; Scardigli, A.; Romani, A.; Macri, G.; Polinori, N.; Bernini, R.; Santi, L. Leishmanicidal activity of green tea leaves and pomegranate peel extracts on L. infantum. Nat Prod Res 2019, 33, 3465–3471. [Google Scholar] [CrossRef]
  52. Mastrogiovanni, F.; Bernini, R.; Basirico, L.; Bernabucci, U.; Campo, M.; Romani, A.; Santi, L.; Lacetera, N. Antioxidant and anti-inflammatory effects of pomegranate peel extracts on bovine mammary epithelial cells BME-UV1. Nat Prod Res 2020, 34, 1465–1469. [Google Scholar] [CrossRef]
  53. Mastrogiovanni, F.; Romani, A.; Santi, L.; Lacetera, N.; Bernini, R. Anti-proliferative effect of pomegranate peel extracts on bovine peripheral blood mononuclear cells (PBMCs). Nat Prod Res 2021, 35, 1696–1701. [Google Scholar] [CrossRef] [PubMed]
  54. Lucarini, M.; Durazzo, A.; Bernini, R.; Campo, M.; Vita, C.; Souto, E.B.; Lombardi-Boccia, G.; Ramadan, M.F.; Santini, A.; Romani, A. Fruit Wastes as a Valuable Source of Value-Added Compounds: A Collaborative Perspective. Molecules 2021, 26. [Google Scholar] [CrossRef] [PubMed]
  55. Noce, A.; Di Lauro, M.; Di Daniele, F.; Pietroboni Zaitseva, A.; Marrone, G.; Borboni, P.; Di Daniele, N. Natural Bioactive Compounds Useful in Clinical Management of Metabolic Syndrome. Nutrients 2021, 13. [Google Scholar] [CrossRef] [PubMed]
  56. Fahed, G.; Aoun, L.; Bou Zerdan, M.; Allam, S.; Bou Zerdan, M.; Bouferraa, Y.; Assi, H.I. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci 2022, 23. [Google Scholar] [CrossRef]
  57. Laurindo, L.F.; Barbalho, S.M.; Marquess, A.R.; Grecco, A.I.S.; Goulart, R.A.; Tofano, R.J.; Bishayee, A. Pomegranate (Punica granatum L.) and Metabolic Syndrome Risk Factors and Outcomes: A Systematic Review of Clinical Studies. Nutrients 2022, 14. [Google Scholar] [CrossRef] [PubMed]
  58. Noce, A.; Romani, A.; Bernini, R. Dietary Intake and Chronic Disease Prevention. Nutrients 2021, 13. [Google Scholar] [CrossRef]
  59. Marrone, G.; Guerriero, C.; Palazzetti, D.; Lido, P.; Marolla, A.; Di Daniele, F.; Noce, A. Vegan Diet Health Benefits in Metabolic Syndrome. Nutrients 2021, 13. [Google Scholar] [CrossRef]
  60. Hou, C.; Zhang, W.; Li, J.; Du, L.; Lv, O.; Zhao, S.; Li, J. Beneficial Effects of Pomegranate on Lipid Metabolism in Metabolic Disorders. Mol Nutr Food Res 2019, 63, e1800773. [Google Scholar] [CrossRef]
  61. Esmaillzadeh, A.; Tahbaz, F.; Gaieni, I.; Alavi-Majd, H.; Azadbakht, L. Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia. J Med Food 2004, 7, 305–308. [Google Scholar] [CrossRef]
  62. Kojadinovic, M.I.; Arsic, A.C.; Debeljak-Martacic, J.D.; Konic-Ristic, A.I.; Kardum, N.D.; Popovic, T.B.; Glibetic, M.D. Consumption of pomegranate juice decreases blood lipid peroxidation and levels of arachidonic acid in women with metabolic syndrome. J Sci Food Agric 2017, 97, 1798–1804. [Google Scholar] [CrossRef]
  63. Banihani, S.; Swedan, S.; Alguraan, Z. Pomegranate and type 2 diabetes. Nutr Res 2013, 33, 341–348. [Google Scholar] [CrossRef] [PubMed]
  64. Huang, T.H.; Peng, G.; Kota, B.P.; Li, G.Q.; Yamahara, J.; Roufogalis, B.D.; Li, Y. Anti-diabetic action of Punica granatum flower extract: activation of PPAR-gamma and identification of an active component. Toxicol Appl Pharmacol 2005, 207, 160–169. [Google Scholar] [CrossRef] [PubMed]
  65. Koren-Gluzer, M.; Aviram, M.; Meilin, E.; Hayek, T. The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates beta-cell insulin release. Atherosclerosis 2011, 219, 510–518. [Google Scholar] [CrossRef] [PubMed]
  66. Seyed Hashemi, M.; Namiranian, N.; Tavahen, H.; Dehghanpour, A.; Rad, M.H.; Jam-Ashkezari, S.; Emtiazy, M.; Hashempur, M.H. Efficacy of Pomegranate Seed Powder on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes: A Prospective Randomized Double-Blind Placebo-Controlled Clinical Trial. Complement Med Res 2021, 28, 226–233. [Google Scholar] [CrossRef] [PubMed]
  67. Gheflati, A.; Mohammadi, M.; Ramezani-Jolfaie, N.; Heidari, Z.; Salehi-Abargouei, A.; Nadjarzadeh, A. Does pomegranate consumption affect weight and body composition? A systematic review and meta-analysis of randomized controlled clinical trials. Phytother Res 2019, 33, 1277–1288. [Google Scholar] [CrossRef] [PubMed]
  68. Al-Muammar, M.N.; Khan, F. Obesity: the preventive role of the pomegranate (Punica granatum). Nutrition 2012, 28, 595–604. [Google Scholar] [CrossRef] [PubMed]
  69. Abidov, M.; Ramazanov, Z.; Seifulla, R.; Grachev, S. The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab 2010, 12, 72–81. [Google Scholar] [CrossRef] [PubMed]
  70. Sohrab, G.; Roshan, H.; Ebrahimof, S.; Nikpayam, O.; Sotoudeh, G.; Siasi, F. Effects of pomegranate juice consumption on blood pressure and lipid profile in patients with type 2 diabetes: A single-blind randomized clinical trial. Clin Nutr ESPEN 2019, 29, 30–35. [Google Scholar] [CrossRef] [PubMed]
  71. Hosseini, B.; Saedisomeolia, A.; Wood, L.G.; Yaseri, M.; Tavasoli, S. Effects of pomegranate extract supplementation on inflammation in overweight and obese individuals: A randomized controlled clinical trial. Complement Ther Clin Pract 2016, 22, 44–50. [Google Scholar] [CrossRef]
  72. Brown, J.S.; Amend, S.R.; Austin, R.H.; Gatenby, R.A.; Hammarlund, E.U.; Pienta, K.J. Updating the Definition of Cancer. Mol Cancer Res 2023, 21, 1142–1147. [Google Scholar] [CrossRef]
  73. Pogribny, I.P.; Rusyn, I. Environmental toxicants, epigenetics, and cancer. Adv Exp Med Biol 2013, 754, 215–232. [Google Scholar] [CrossRef] [PubMed]
  74. Tiffon, C. The Impact of Nutrition and Environmental Epigenetics on Human Health and Disease. Int J Mol Sci 2018, 19. [Google Scholar] [CrossRef] [PubMed]
  75. Katzke, V.A.; Kaaks, R.; Kuhn, T. Lifestyle and cancer risk. Cancer J 2015, 21, 104–110. [Google Scholar] [CrossRef] [PubMed]
  76. Narimatsu, H.; Yaguchi, Y.T. The Role of Diet and Nutrition in Cancer: Prevention, Treatment, and Survival. Nutrients 2022, 14. [Google Scholar] [CrossRef] [PubMed]
  77. Garcia-Montero, C.; Fraile-Martinez, O.; Gomez-Lahoz, A.M.; Pekarek, L.; Castellanos, A.J.; Noguerales-Fraguas, F.; Coca, S.; Guijarro, L.G.; Garcia-Honduvilla, N.; Asunsolo, A. , et al. Nutritional Components in Western Diet Versus Mediterranean Diet at the Gut Microbiota-Immune System Interplay. Implications for Health and Disease. Nutrients 2021, 13. [Google Scholar] [CrossRef] [PubMed]
  78. Di Daniele, N.; Noce, A.; Vidiri, M.F.; Moriconi, E.; Marrone, G.; Annicchiarico-Petruzzelli, M.; D'Urso, G.; Tesauro, M.; Rovella, V.; De Lorenzo, A. Impact of Mediterranean diet on metabolic syndrome, cancer and longevity. Oncotarget 2017, 8, 8947–8979. [Google Scholar] [CrossRef] [PubMed]
  79. Marrone, G.; Urciuoli, S.; Candi, E.; Bernini, R.; Vanni, G.; Masci, C.; Guerriero, C.; Mancini, M.; De Lorenzo, A.; Vignolini, P. , et al. Biological Activities of Molecules Derived from Olea europaea L. Tested In Vitro. Life 2024, 14, 49. [Google Scholar] [CrossRef] [PubMed]
  80. Turati, F.; Rossi, M.; Pelucchi, C.; Levi, F.; La Vecchia, C. Fruit and vegetables and cancer risk: a review of southern European studies. Br J Nutr 2015, 113 Suppl 2, S102–110. [Google Scholar] [CrossRef]
  81. Tete, S.; Nicoletti, M.; Saggini, A.; Maccauro, G.; Rosati, M.; Conti, F.; Cianchetti, E.; Tripodi, D.; Toniato, E.; Fulcheri, M. , et al. Nutrition and cancer prevention. Int J Immunopathol Pharmacol 2012, 25, 573–581. [Google Scholar] [CrossRef]
  82. Sharma, P.; McClees, S.F.; Afaq, F. Pomegranate for Prevention and Treatment of Cancer: An Update. Molecules 2017, 22. [Google Scholar] [CrossRef]
  83. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J Clin 2015, 65, 87–108. [Google Scholar] [CrossRef] [PubMed]
  84. Noce, A.; Marrone, G.; Materazzo, M.; Vanni, G. Editorial - Beyond breast cancer care: exploring pleiotropic effects of nutritional treatment for breast cancer patients. Eur Rev Med Pharmacol Sci 2022, 26, 5312–5315. [Google Scholar] [CrossRef] [PubMed]
  85. Adams, L.S.; Zhang, Y.; Seeram, N.P.; Heber, D.; Chen, S. Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. Cancer Prev Res (Phila) 2010, 3, 108–113. [Google Scholar] [CrossRef] [PubMed]
  86. Chen, H.S.; Bai, M.H.; Zhang, T.; Li, G.D.; Liu, M. Ellagic acid induces cell cycle arrest and apoptosis through TGF-beta/Smad3 signaling pathway in human breast cancer MCF-7 cells. Int J Oncol 2015, 46, 1730–1738. [Google Scholar] [CrossRef] [PubMed]
  87. Costantini, S.; Rusolo, F.; De Vito, V.; Moccia, S.; Picariello, G.; Capone, F.; Guerriero, E.; Castello, G.; Volpe, M.G. Potential anti-inflammatory effects of the hydrophilic fraction of pomegranate (Punica granatum L.) seed oil on breast cancer cell lines. Molecules 2014, 19, 8644–8660. [Google Scholar] [CrossRef]
  88. Shirode, A.B.; Kovvuru, P.; Chittur, S.V.; Henning, S.M.; Heber, D.; Reliene, R. Antiproliferative effects of pomegranate extract in MCF-7 breast cancer cells are associated with reduced DNA repair gene expression and induction of double strand breaks. Mol Carcinog 2014, 53, 458–470. [Google Scholar] [CrossRef] [PubMed]
  89. Mandal, A.; Bishayee, A. Mechanism of Breast Cancer Preventive Action of Pomegranate: Disruption of Estrogen Receptor and Wnt/beta-Catenin Signaling Pathways. Molecules 2015, 20, 22315–22328. [Google Scholar] [CrossRef]
  90. The, L. Lung cancer: some progress, but still a lot more to do. Lancet 2019, 394, 1880. [Google Scholar] [CrossRef]
  91. Malhotra, J.; Malvezzi, M.; Negri, E.; La Vecchia, C.; Boffetta, P. Risk factors for lung cancer worldwide. Eur Respir J 2016, 48, 889–902. [Google Scholar] [CrossRef]
  92. Wang, C.; Yang, T.; Guo, X.F.; Li, D. The Associations of Fruit and Vegetable Intake with Lung Cancer Risk in Participants with Different Smoking Status: A Meta-Analysis of Prospective Cohort Studies. Nutrients 2019, 11. [Google Scholar] [CrossRef]
  93. Li, Y.; Yang, F.; Zheng, W.; Hu, M.; Wang, J.; Ma, S.; Deng, Y.; Luo, Y.; Ye, T.; Yin, W. Punica granatum (pomegranate) leaves extract induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in non-small cell lung cancer in vitro. Biomed Pharmacother 2016, 80, 227–235. [Google Scholar] [CrossRef] [PubMed]
  94. Husari, A.; Khayat, A.; Bitar, H.; Hashem, Y.; Rizkallah, A.; Zaatari, G.; El Sabban, M. Antioxidant activity of pomegranate juice reduces acute lung injury secondary to hyperoxia in an animal model. BMC Res Notes 2014, 7, 664. [Google Scholar] [CrossRef] [PubMed]
  95. Khan, N.; Hadi, N.; Afaq, F.; Syed, D.N.; Kweon, M.H.; Mukhtar, H. Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 2007, 28, 163–173. [Google Scholar] [CrossRef]
  96. Khan, N.; Afaq, F.; Kweon, M.H.; Kim, K.; Mukhtar, H. Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res 2007, 67, 3475–3482. [Google Scholar] [CrossRef] [PubMed]
  97. Weitz, J.; Koch, M.; Debus, J.; Hohler, T.; Galle, P.R.; Buchler, M.W. Colorectal cancer. Lancet 2005, 365, 153–165. [Google Scholar] [CrossRef] [PubMed]
  98. Ma, Y.; Hu, M.; Zhou, L.; Ling, S.; Li, Y.; Kong, B.; Huang, P. Dietary fiber intake and risks of proximal and distal colon cancers: A meta-analysis. Medicine (Baltimore) 2018, 97, e11678. [Google Scholar] [CrossRef] [PubMed]
  99. Cronin, P.; Joyce, S.A.; O'Toole, P.W.; O'Connor, E.M. Dietary Fibre Modulates the Gut Microbiota. Nutrients 2021, 13. [Google Scholar] [CrossRef]
  100. Thanikachalam, K.; Khan, G. Colorectal Cancer and Nutrition. Nutrients 2019, 11. [Google Scholar] [CrossRef] [PubMed]
  101. Gianfredi, V.; Salvatori, T.; Villarini, M.; Moretti, M.; Nucci, D.; Realdon, S. Is dietary fibre truly protective against colon cancer? A systematic review and meta-analysis. Int J Food Sci Nutr 2018, 69, 904–915. [Google Scholar] [CrossRef]
  102. Singh, J.; Kaur, H.P.; Verma, A.; Chahal, A.S.; Jajoria, K.; Rasane, P.; Kaur, S.; Kaur, J.; Gunjal, M.; Ercisli, S. , et al. Pomegranate Peel Phytochemistry, Pharmacological Properties, Methods of Extraction, and Its Application: A Comprehensive Review. ACS Omega 2023, 8, 35452–35469. [Google Scholar] [CrossRef]
  103. Wang, L.; Chen, J.; Chen, Q.; Song, H.; Wang, Z.; Xing, W.; Jin, S.; Song, X.; Yang, H.; Zhao, W. The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B. Oxid Med Cell Longev 2023, 2023, 6480848. [Google Scholar] [CrossRef] [PubMed]
  104. Kasimsetty, S.G.; Bialonska, D.; Reddy, M.K.; Ma, G.; Khan, S.I.; Ferreira, D. Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J Agric Food Chem 2010, 58, 2180–2187. [Google Scholar] [CrossRef] [PubMed]
  105. Cui, J.; Jia, J. Natural COX-2 Inhibitors as Promising Anti-inflammatory Agents: An Update. Curr Med Chem 2021, 28, 3622–3646. [Google Scholar] [CrossRef] [PubMed]
  106. Fournier, D.B.; Gordon, G.B. COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem Suppl 2000, 34, 97–102. [Google Scholar] [CrossRef]
  107. Kohno, H.; Suzuki, R.; Yasui, Y.; Hosokawa, M.; Miyashita, K.; Tanaka, T. Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis in rats. Cancer Sci 2004, 95, 481–486. [Google Scholar] [CrossRef] [PubMed]
  108. Nguyen-Nielsen, M.; Borre, M. Diagnostic and Therapeutic Strategies for Prostate Cancer. Semin Nucl Med 2016, 46, 484–490. [Google Scholar] [CrossRef] [PubMed]
  109. Lopez-Ferber, M.; Comendador, M.A. Transmission of the hereditary S character in Drosophila simulans: effects of aging and temperature treatments. J Invertebr Pathol 1992, 59, 264–270. [Google Scholar] [CrossRef]
  110. Adjakly, M.; Ngollo, M.; Dagdemir, A.; Judes, G.; Pajon, A.; Karsli-Ceppioglu, S.; Penault-Llorca, F.; Boiteux, J.P.; Bignon, Y.J.; Guy, L. , et al. Prostate cancer: The main risk and protective factors-Epigenetic modifications. Ann Endocrinol (Paris) 2015, 76, 25–41. [Google Scholar] [CrossRef] [PubMed]
  111. Albrecht, M.; Jiang, W.; Kumi-Diaka, J.; Lansky, E.P.; Gommersall, L.M.; Patel, A.; Mansel, R.E.; Neeman, I.; Geldof, A.A.; Campbell, M.J. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 2004, 7, 274–283. [Google Scholar] [CrossRef]
  112. Wang, Y.; Zhang, S.; Iqbal, S.; Chen, Z.; Wang, X.; Wang, Y.A.; Liu, D.; Bai, K.; Ritenour, C.; Kucuk, O. , et al. Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy. Prostate, 1002. [Google Scholar] [CrossRef]
  113. Lee, S.T.; Wu, Y.L.; Chien, L.H.; Chen, S.T.; Tzeng, Y.K.; Wu, T.F. Proteomic exploration of the impacts of pomegranate fruit juice on the global gene expression of prostate cancer cell. Proteomics 2012, 12, 3251–3262. [Google Scholar] [CrossRef]
  114. Hong, M.Y.; Seeram, N.P.; Heber, D. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J Nutr Biochem 2008, 19, 848–855. [Google Scholar] [CrossRef]
  115. Matsushita, M.; Fujita, K.; Nonomura, N. Influence of Diet and Nutrition on Prostate Cancer. Int J Mol Sci 2020, 21. [Google Scholar] [CrossRef]
  116. Yin, Y.; Martinez, R.; Zhang, W.; Estevez, M. Crosstalk between dietary pomegranate and gut microbiota: evidence of health benefits. Crit Rev Food Sci Nutr, 1080. [Google Scholar] [CrossRef]
  117. Marrone, G.; Di Lauro, M.; Izzo, F.; Cornali, K.; Masci, C.; Vita, C.; Occhiuto, F.; Di Daniele, N.; De Lorenzo, A.; Noce, A. Possible Beneficial Effects of Hydrolyzable Tannins Deriving from Castanea sativa L. in Internal Medicine. Nutrients 2023, 16. [Google Scholar] [CrossRef]
  118. Howell, A.B.; D'Souza, D.H. The pomegranate: effects on bacteria and viruses that influence human health. Evid Based Complement Alternat Med 2013, 2013, 606212. [Google Scholar] [CrossRef] [PubMed]
  119. Sharma, A.; Chandraker, S.; Patel, V.K.; Ramteke, P. Antibacterial Activity of Medicinal Plants Against Pathogens causing Complicated Urinary Tract Infections. Indian J Pharm Sci 2009, 71, 136–139. [Google Scholar] [CrossRef] [PubMed]
  120. Holoch, P.A.; Tracy, C.R. Antioxidants and self-reported history of kidney stones: the National Health and Nutrition Examination Survey. J Endourol 2011, 25, 1903–1908. [Google Scholar] [CrossRef] [PubMed]
  121. Tracy, C.R.; Henning, J.R.; Newton, M.R.; Aviram, M.; Bridget Zimmerman, M. Oxidative stress and nephrolithiasis: a comparative pilot study evaluating the effect of pomegranate extract on stone risk factors and elevated oxidative stress levels of recurrent stone formers and controls. Urolithiasis 2014, 42, 401–408. [Google Scholar] [CrossRef]
  122. Tugcu, V.; Kemahli, E.; Ozbek, E.; Arinci, Y.V.; Uhri, M.; Erturkuner, P.; Metin, G.; Seckin, I.; Karaca, C.; Ipekoglu, N. , et al. Protective effect of a potent antioxidant, pomegranate juice, in the kidney of rats with nephrolithiasis induced by ethylene glycol. J Endourol 2008, 22, 2723–2731. [Google Scholar] [CrossRef]
  123. McDowell, C.; Farooq, U.; Haseeb, M. Inflammatory Bowel Disease. In StatPearls, Treasure Island (FL) with ineligible companies. Disclosure: Umer Farooq declares no relevant financial relationships with ineligible companies. Disclosure: Muhammad Haseeb declares no relevant financial relationships with ineligible companies., 2023.
  124. Colombo, E.; Sangiovanni, E.; Dell'agli, M. A review on the anti-inflammatory activity of pomegranate in the gastrointestinal tract. Evid Based Complement Alternat Med 2013, 2013, 247145. [Google Scholar] [CrossRef]
  125. Li, H.; Ruan, J.; Huang, J.; Yang, D.; Yu, H.; Wu, Y.; Zhang, Y.; Wang, T. Pomegranate (Punica granatum L.) and Its Rich Ellagitannins as Potential Inhibitors in Ulcerative Colitis. Int J Mol Sci 2023, 24. [Google Scholar] [CrossRef]
  126. Scaioli, E.; Belluzzi, A.; Ricciardiello, L.; Del Rio, D.; Rotondo, E.; Mena, P.; Derlindati, E.; Danesi, F. Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial. Trials 2019, 20, 327. [Google Scholar] [CrossRef] [PubMed]
  127. Zhao, R.; Long, X.; Yang, J.; Du, L.; Zhang, X.; Li, J.; Hou, C. Pomegranate peel polyphenols reduce chronic low-grade inflammatory responses by modulating gut microbiota and decreasing colonic tissue damage in rats fed a high-fat diet. Food Funct 2019, 10, 8273–8285. [Google Scholar] [CrossRef] [PubMed]
  128. Marin, M.; Maria Giner, R.; Rios, J.L.; Recio, M.C. Intestinal anti-inflammatory activity of ellagic acid in the acute and chronic dextrane sulfate sodium models of mice colitis. J Ethnopharmacol 2013, 150, 925–934. [Google Scholar] [CrossRef] [PubMed]
  129. Kim, Y.E.; Hwang, C.J.; Lee, H.P.; Kim, C.S.; Son, D.J.; Ham, Y.W.; Hellstrom, M.; Han, S.B.; Kim, H.S.; Park, E.K. , et al. Inhibitory effect of punicalagin on lipopolysaccharide-induced neuroinflammation, oxidative stress and memory impairment via inhibition of nuclear factor-kappaB. Neuropharmacology 2017, 117, 21–32. [Google Scholar] [CrossRef]
  130. Essa, M.M.; Subash, S.; Akbar, M.; Al-Adawi, S.; Guillemin, G.J. Long-term dietary supplementation of pomegranates, figs and dates alleviate neuroinflammation in a transgenic mouse model of Alzheimer's disease. PLoS One 2015, 10, e0120964. [Google Scholar] [CrossRef]
  131. Velagapudi, R.; Baco, G.; Khela, S.; Okorji, U.; Olajide, O. Pomegranate inhibits neuroinflammation and amyloidogenesis in IL-1beta-stimulated SK-N-SH cells. Eur J Nutr 2016, 55, 1653–1660. [Google Scholar] [CrossRef]
  132. Loren, D.J.; Seeram, N.P.; Schulman, R.N.; Holtzman, D.M. Maternal dietary supplementation with pomegranate juice is neuroprotective in an animal model of neonatal hypoxic-ischemic brain injury. Pediatr Res 2005, 57, 858–864. [Google Scholar] [CrossRef]
  133. Braidy, N.; Essa, M.M.; Poljak, A.; Selvaraju, S.; Al-Adawi, S.; Manivasagm, T.; Thenmozhi, A.J.; Ooi, L.; Sachdev, P.; Guillemin, G.J. Consumption of pomegranates improves synaptic function in a transgenic mice model of Alzheimer's disease. Oncotarget 2016, 7, 64589–64604. [Google Scholar] [CrossRef]
  134. Subash, S.; Essa, M.M.; Al-Asmi, A.; Al-Adawi, S.; Vaishnav, R.; Braidy, N.; Manivasagam, T.; Guillemin, G.J. Pomegranate from Oman Alleviates the Brain Oxidative Damage in Transgenic Mouse Model of Alzheimer's disease. J Tradit Complement Med 2014, 4, 232–238. [Google Scholar] [CrossRef]
  135. Ciccone, L.; Nencetti, S.; Rossello, A.; Orlandini, E. Pomegranate: A Source of Multifunctional Bioactive Compounds Potentially Beneficial in Alzheimer's Disease. Pharmaceuticals (Basel) 2023, 16. [Google Scholar] [CrossRef]
  136. Bhadbhade, S.J.; Acharya, A.B.; Rodrigues, S.V.; Thakur, S.L. The antiplaque efficacy of pomegranate mouthrinse. Quintessence Int 2011, 42, 29–36. [Google Scholar]
  137. Pereira, J.; Silva Filho, S.; LS, H.J. Antimicrobial activity of hyroalcoholic extract of Punica granatum Linn. on plaque forming microorganisms. Periodontics Rev 2001, 12, 57–64. [Google Scholar]
  138. Pereira, J.; Pereira, M.; Higino, J.; Sampio, F.; Alves, P.; Araujo, C. Studies with the extract of the Punica granatum Linn.(Pomegranate): Antimicrobial effect “in vitro” and clinical evaluation of a toothpaste upon microorganisms of the oral biofilm. Journal of Dental Science 2005, 20, 262–269. [Google Scholar]
  139. Deepak, J.C.; Samuel, S.R. Effectiveness of Pomegranate Mouthrinse in Reducing Bacterial Plaque, Gingival Inflammation and Total Salivary Proteins over a Period of 90 Days: A Double-Blind Randomized Trial. J Int Acad Periodontol 2018, 20, 110–114. [Google Scholar] [PubMed]
  140. Vahabi, S.; Najafi, E.; Alizadeh, S. In vitro antimicrobial effects of some herbal essences against oral pathogens. JOURNAL OF MEDICINAL PLANTS RESEARCH 2011, 15, 4870–4878. [Google Scholar] [CrossRef]
  141. Carranza, F.A.; Newman, M.G.; Takei, H.H.; Klokkevold, P.R. Carranza's clinical periodontology, 10th ed ed.; Saunders Elsevier St. Louis, Mo.: St. Louis, Mo, 2006. [Google Scholar]
  142. Koh, K.H.; Tham, F.Y. Screening of traditional Chinese medicinal plants for quorum-sensing inhibitors activity. J Microbiol Immunol Infect 2011, 44, 144–148. [Google Scholar] [CrossRef] [PubMed]
  143. Menezes, S.M.; Cordeiro, L.N.; Viana, G.S. Punica granatum (pomegranate) extract is active against dental plaque. J Herb Pharmacother 2006, 6, 79–92. [Google Scholar] [CrossRef] [PubMed]
  144. Deswal, H.; Singh, Y.; Grover, H.S.; Bhardwaj, A. Pomegranate as an Curative Therapy in Medical and Dental Sciences: A review. Innovare Journal of Medical Sciences 2016, 4, 15–18. [Google Scholar]
  145. Salgado, A.D.; Maia, J.L.; Pereira, S.L.; de Lemos, T.L.; Mota, O.M. Antiplaque and antigingivitis effects of a gel containing Punica granatum Linn extract: a double-blind clinical study in humans. J Appl Oral Sci 2006, 14, 162–166. [Google Scholar] [CrossRef]
  146. Sharma, U.; Jain, R.L.; Pathak, A. A clinical assessment of the effectiveness of mouthwashes in comparison to toothbrushing in children. J Indian Soc Pedod Prev Dent 2004, 22, 38–44. [Google Scholar]
  147. Shaila, M.; Pai, G.P.; Shetty, P. Salivary protein concentration, flow rate, buffer capacity and pH estimation: A comparative study among young and elderly subjects, both normal and with gingivitis and periodontitis. J Indian Soc Periodontol 2013, 17, 42–46. [Google Scholar] [CrossRef] [PubMed]
  148. Kote, S.; Kote, S.; Nagesh, L. Effect of pomegranate juice on dental plaque microorganisms (streptococci and lactobacilli). Anc Sci Life 2011, 31, 49–51. [Google Scholar] [PubMed]
  149. Ahuja, S.; Dodwad, V.; Kukreja, B.; Mehra, P.; Kukreja, P. A comparative evaluation of efficacy of Punica granatum and chlorhexidine on plaque and gingivitis. Journal of the International Clinical Dental Research Organization 2011, 3, 29. [Google Scholar] [CrossRef]
  150. DiSilvestro, R.A.; DiSilvestro, D.J.; DiSilvestro, D.J. Pomegranate extract mouth rinsing effects on saliva measures relevant to gingivitis risk. Phytother Res 2009, 23, 1123–1127. [Google Scholar] [CrossRef] [PubMed]
  151. Somu, C.A.; Ravindra, S.; Ajith, S.; Ahamed, M.G. Efficacy of a herbal extract gel in the treatment of gingivitis: A clinical study. J Ayurveda Integr Med 2012, 3, 85–90. [Google Scholar] [CrossRef]
  152. Sastravaha, G.; Gassmann, G.; Sangtherapitikul, P.; Grimm, W.D. Adjunctive periodontal treatment with Centella asiatica and Punica granatum extracts in supportive periodontal therapy. J Int Acad Periodontol 2005, 7, 70–79. [Google Scholar]
  153. Bialonska, D.; Ramnani, P.; Kasimsetty, S.G.; Muntha, K.R.; Gibson, G.R.; Ferreira, D. The influence of pomegranate by-product and punicalagins on selected groups of human intestinal microbiota. Int J Food Microbiol 2010, 140, 175–182. [Google Scholar] [CrossRef] [PubMed]
  154. Umeda, M.; Kobayashi, H.; Takeuchi, Y.; Hayashi, J.; Morotome-Hayashi, Y.; Yano, K.; Aoki, A.; Ohkusa, T.; Ishikawa, I. High prevalence of Helicobacter pylori detected by PCR in the oral cavities of periodontitis patients. J Periodontol 2003, 74, 129–134. [Google Scholar] [CrossRef]
  155. Prasad, D.; Kunnaiah, R. Punica granatum: A review on its potential role in treating periodontal disease. J Indian Soc Periodontol 2014, 18, 428–432. [Google Scholar] [CrossRef]
  156. Narayan, T.; S, D.; A, J.; Vasthare, R. Punica granatum (Pomegranate) fruit and its relevance in Oral Hygiene. IOSR Journal of Dental and Medical Sciences 2014, 13, 29–34. [Google Scholar] [CrossRef]
  157. Gawor, J.P.; Ziemann, D.; Nicolas, C.S. A water additive with pomegranate can reduce dental plaque and calculus accumulation in dogs. Front Vet Sci 2023, 10, 1241197. [Google Scholar] [CrossRef] [PubMed]
  158. Batista, A.L.; Lins, R.D.; de Souza Coelho, R.; do Nascimento Barbosa, D.; Moura Belem, N.; Alves Celestino, F.J. Clinical efficacy analysis of the mouth rinsing with pomegranate and chamomile plant extracts in the gingival bleeding reduction. Complement Ther Clin Pract 2014, 20, 93–98. [Google Scholar] [CrossRef] [PubMed]
  159. Ghalayani, P.; Zolfaghary, B.; Farhad, A.R.; Tavangar, A.; Soleymani, B. The efficacy of Punica granatum extract in the management of recurrent aphthous stomatitis. J Res Pharm Pract 2013, 2, 88–92. [Google Scholar] [CrossRef] [PubMed]
  160. Jha, M. In Vivo Topical Wound Healing Activity of Punica Granatum Peel Extract on Rats. American Journal of Phytomedicine and Clinical Therapeutics 2013, 1, 195. [Google Scholar]
  161. Tavassoli-Hojjati, S.; Aliasghar, E.; Babaki, F.A.; Emadi, F.; Parsa, M.; Tavajohi, S.; Ahmadyar, M.; Ostad, S.N. Pomegranate juice (punica granatum): a new storage medium for avulsed teeth. J Dent (Tehran) 2014, 11, 225–232. [Google Scholar] [PubMed]
  162. van der Ouderaa, F.J. Anti-plaque agents. Rationale and prospects for prevention of gingivitis and periodontal disease. J Clin Periodontol 1991, 18, 447–454. [Google Scholar] [CrossRef] [PubMed]
  163. Vasconcelos, L.C.; Sampaio, M.C.; Sampaio, F.C.; Higino, J.S. Use of Punica granatum as an antifungal agent against candidosis associated with denture stomatitis. Mycoses 2003, 46, 192–196. [Google Scholar] [CrossRef]
  164. Kandra, L.; Gyemant, G.; Zajacz, A.; Batta, G. Inhibitory effects of tannin on human salivary alpha-amylase. Biochem Biophys Res Commun 2004, 319, 1265–1271. [Google Scholar] [CrossRef] [PubMed]
  165. Scannapieco, F.A.; Torres, G.; Levine, M.J. Salivary alpha-amylase: role in dental plaque and caries formation. Crit Rev Oral Biol Med 1993, 4, 301–307. [Google Scholar] [CrossRef]
  166. Li, Y.; Wen, S.; Kota, B.P.; Peng, G.; Li, G.Q.; Yamahara, J.; Roufogalis, B.D. Punica granatum flower extract, a potent alpha-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats. J Ethnopharmacol 2005, 99, 239–244. [Google Scholar] [CrossRef]
  167. Halliwell, B.; Zhao, K.; Whiteman, M. The gastrointestinal tract: a major site of antioxidant action? Free Radic Res 2000, 33, 819–830. [Google Scholar] [CrossRef] [PubMed]
  168. Nomura, Y.; Tamaki, Y.; Tanaka, T.; Arakawa, H.; Tsurumoto, A.; Kirimura, K.; Sato, T.; Hanada, N.; Kamoi, K. Screening of periodontitis with salivary enzyme tests. J Oral Sci 2006, 48, 177–183. [Google Scholar] [CrossRef] [PubMed]
  169. Boussetta, T.; Raad, H.; Letteron, P.; Gougerot-Pocidalo, M.A.; Marie, J.C.; Driss, F.; El-Benna, J. Punicic acid a conjugated linolenic acid inhibits TNFalpha-induced neutrophil hyperactivation and protects from experimental colon inflammation in rats. PLoS One 2009, 4, e6458. [Google Scholar] [CrossRef] [PubMed]
  170. Lee, C.-J.; Chen, L.-G.; Liang, W.-L.; Wang, C.-C. Anti-inflammatory effects of Punica granatum Linne in vitro and in vivo. Food Chemistry 2010, 118, 315–322. [Google Scholar] [CrossRef]
  171. Elkarkhy, Y.; Mahmoud, G.; Alla, A.; Abass, A. The Antibacterial Effect of Pomegranate Peel and Guava Leave Extract Mouthwash on Oral Streptococcus Mutans in Scholar Students: A Controlled Clinical Study. Al-Azhar Journal of Dental Science 2022, 25, 359–363. [Google Scholar] [CrossRef]
  172. Brookes, Z.L.S.; Bescos, R.; Belfield, L.A.; Ali, K.; Roberts, A. Current uses of chlorhexidine for management of oral disease: a narrative review. J Dent 2020, 103, 103497. [Google Scholar] [CrossRef] [PubMed]
  173. James, P.; Worthington, H.V.; Parnell, C.; Harding, M.; Lamont, T.; Cheung, A.; Whelton, H.; Riley, P. Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database Syst Rev 2017, 3, CD008676. [Google Scholar] [CrossRef]
  174. Marya, C.; Singroha, S.; Nagpal, R.; Taneja, P.; Kataria, S.; Kashyap, P. Effect of pomegranate mouthrinse on gingival health: A 21 day randomised controlled clinical trial. Journal of Indian Association of Public Health Dentistry 2022, 20, 427–431. [Google Scholar] [CrossRef]
Preprints 97310 g001
Figure 1. Biological activities of bioactive polyphenolic compounds of pomegranate.
Figure 1. Biological activities of bioactive polyphenolic compounds of pomegranate.
Preprints 97310 g001
Preprints 97310 g002
Figure 2. Circular economy model for pomegranate wastes recovery.
Figure 2. Circular economy model for pomegranate wastes recovery.
Preprints 97310 g002
Preprints 97310 g003
Figure 3. Beneficial effects of pomegranate in internal medicine.
Figure 3. Beneficial effects of pomegranate in internal medicine.
Preprints 97310 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated